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Abstract
Background: We are developing a cross-species comparison strategy to distinguish between cancer driver- and
passenger gene alteration candidates, by utilizing the difference in genomic location of orthologous genes
between the human and other mammals. As an initial test of this strategy, we conducted a pilot study with
human colorectal cancer (CRC) and its mouse model C57BL/6J Apc
Min/+, focusing on human 5q22.2 and
18q21.1-q21.2.
Methods: We first performed bioinformatics analysis on the evolution of 5q22.2 and 18q21.1-q21.2 regions. Then,
we performed exon-targeted sequencing, real time quantitative polymerase chain reaction (qPCR), and real time
quantitative reverse transcriptase PCR (qRT-PCR) analyses on a number of genes of both regions with both human
and mouse colon tumors.
Results: These two regions (5q22.2 and 18q21.1-q21.2) are frequently deleted in human CRCs and encode genuine
colorectal tumor suppressors APC and SMAD4. They also encode genes such as MCC (mutated in colorectal cancer)
with their role in CRC etiology unknown. We have discovered that both regions are evolutionarily unstable,
resulting in genes that are clustered in each human region being found scattered at several distinct loci in the
genome of many other species. For instance, APC and MCC are within 200 kb apart in human 5q22.2 but are
10 Mb apart in the mouse genome. Importantly, our analyses revealed that, while known CRC driver genes APC
and SMAD4 were disrupted in both human colorectal tumors and tumors from Apc
Min/+ mice, the questionable
MCC gene was disrupted in human tumors but appeared to be intact in mouse tumors.
Conclusions: These results indicate that MCC may not actually play any causative role in early colorectal
tumorigenesis. We also hypothesize that its disruption in human CRCs is likely a mere result of its close proximity
to APC in the human genome. Expanding this pilot study to the entire genome may identify more questionable
genes like MCC, facilitating the discovery of new CRC driver gene candidates.
Background
Cancer is a disease of the genome. As cancer initiates
and progresses, genomic instability develops and abnor-
mal genomic changes (e.g., sequence mutations, aberrant
promoter methylation, and structural lesions such as
gains/losses, inversions and translocations) accumulate
[1-6]. While some of these abnormalities disrupt normal
cellular processes and contribute to cancer initiation
and progression (i.e., drivers), others emerge simply as
victims of genomic instability occurring as a result of
cancer progression (i.e., passengers). Clearly, finding
genomic abnormalities is significant, but identifying
those that are cancer-drivers is even more meaningful.
A central aim of cancer research has been to identify
driver gene alterations. This has become both urgent
and increasingly challenging in recent years with the
advance of sequencing and other technologies [7] as
well as the launch of high-throughput cancer genome
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ome.nih.gov), the International Cancer Genome Consor-
tium http://www.icgc.org, and others [3,4]. Researchers
have been tackling this chal l e n g eb yi m p r o v i n ge x p e r i -
mental conditions [5] and developing more sophisticated
statistical models and functional analysis strategies
[3,4,6].
We are developing a cross-species comparison strategy
that differs fundamentally from the current published
approaches described above (which study human can-
cers only). We hypothesize that driver alteration candi-
dates can be distinguished from passenger candidates
through examination of orthologous genes or genomic
loci with tumors from multiple species having the same
type of cancer. Provided that these species share similar
molecular and genetic pathways of cancer development
and progression, abnormalities that are recurrent among
different species will have a higher probability to be dri-
vers, whereas those that are found in only one species
and are located in evolutionarily unstable sites will be
more likely to be passengers. In our studies, evolutiona-
rily unstable sites are defined as regions enriched with
interspecies genomic rearrangement breakpoints [8,9].
However, we do acknowledge that our strategy will not
be able to identify species-specific drivers.
Our strategy rests on the same rationale that cancer
researchers have been using for years: abnormalities
recurrent among different cases are more likely to be
drivers, compared with non-recurrent events. The differ-
ence is that we are searching for events that are recur-
rent not only among different cases within the same
species, but also among different species. One significant
advantage of our cross-species comparison strategy has
over single-species approaches is that it utilizes the dif-
ference in the genomic location of orthologous genes
and loci, caused by interspecies genomic rearrangements
that occurred during evolution, for driver and passenger
alteration distinction. The pilot study illustrating this is
described here, which compared human colorectal can-
cer (CRC) and one of its mouse models C57BL/6J (B6)
Apc
Min/+ [10,11] on genes encoded in two evolutionarily
unstable human genomic regions 5q22.2 and 18q21.1-
q21.2.
Human CRC is one of the better understood systems
for studying the genetics of cancer initiation and pro-
gression [12-17]. The stepwise model of human CRC
development and progression proposed by Vogelstein
and colleagues [12,13] (Figure 1) includes: 1) inactiva-
tion of the APC, SMAD4,a n dP53 tumor suppressors;
2) overactivation of the KRAS oncogene; and 3) develop-
ment of genomic instability in the form of either chro-
mosomal instability (CIN) [12-16] or microsatellite
instability (MSI) [16,17].
The human 5q22.2 and 18q21.1-q21.2 regions are
both constantly disrupted in human CRCs [15,16], and
encode bona fide CRC driver genes (e.g., APC, SMAD4)
as well as genes whose role in cancer etiology remains
unclear (e.g., mutated in colorectal cancer or MCC). By
comparison with different species, we found that both
regions are evolutionarily unstable and prone to inter-
species genomic rearrangements during evolution. As a
consequence, genes clustered in each human region
were, by contrast, found scattered at several different
loci in the genome of many other species, including the
mouse. We investigated these genes in colon tumors
from humans as well as a well-known CRC mouse
model B6 Apc
Min/+ [10,11]. We found that, while bona
fide driver genes APC and SMAD4 were indeed dis-
rupted in both species (another CRC gene P53, located
in a different site 17p, was also altered), the questionable
MCC was altered in human tumors but appeared to be
structurally and expressionally intact in mouse tumors.
Our results indicate that MCC is unlikely a player in
early colorectal tumorigenesis, and we hypothesize that
its disruption in human colorectal tumors is most likely
a mere result of its close proximity to APC in the
human genome. This study has demonstrated the pro-
mise of using this cross-species comparative genomics
and oncology strategy for distinguishing between CRC
driver- and passenger gene alteration candidates.
Figure 1 The human colorectal tumorigenesis model proposed by Vogelstein and colleagues [12,13] describes sequential inactivation
of tumor suppressors (APC, SMAD4, and P53), activation of oncogene KRAS, and development of genomic instability. However, genes
that are near the bona fide tumor suppressors and are disrupted in the human CRC appear not to be cancer-drivers, based on mouse model
studies (DCC) or due to lack of evidence for the contribution to cancer (MCC).
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Materials
Human DNA samples purified from 40 normal/tumor
paired tissues of sporadic Dukes B tumors were pro-
vided by Dr. Timothy J. Yeatman from H. Lee Moffitt
Cancer Center and Research Institute in Florida. Dr.
Yeatman has been approved for human subject use by
Institutional Review Boards of the University of South
Florida. Colonic adenomas and matching normal tissues
from several B6 Apc
Min/+ mice were provided by Dr.
Richard Halberg of the University of Wisconsin (UW) in
Madison and Dr. Maria Marjorette O. Peña of the
M o u s eC o r eF a c i l i t yo ft h eC e n t e rf o rC o l o nC a n c e r
Research of the University of South Carolina (USC). All
animal studies were conducted under protocols
approved by the Institutional Animal Care and Use
Committee of UW and USC, following the guidelines of
the American Association for the Assessment and
Accreditation of Laboratory Animal Care. Genomic
DNA samples were extracted from these tissues using
the QIAGEN DNeasy Tissue kit.
Comparative genomics and sequence analyses
The genomic sequence and annotation data of human
5q22.2 and 18q21.1-q21.2 asw e l la st h e i rh o m o l o g u e s
from other species were downloaded from the Ensembl
site at http://www.ensembl.org and the University
of California Santa Cruz genome site at http://www.-
genome.ucsc.edu. Sequences of different species were
aligned through comparison with the BLATN program
and/or by examining the gene order of each species.
Evolutionary breakpoints were identified by examining
the alignments. Repetitive sequences were identified by
using the RepeatMasker program obtained from http://
www.repeatmasker.org.
Bi-directional exon resequencing and mutation detection
Sequencing was performed at The J. Craig Venter Insti-
tute in Maryland following the established protocols.
Briefly, primers were designed based on genomic
sequences obtained from the Ensembl site, flanking each
exon or within the exon (for big exons) with ~400-800
bp distance apart. Then, the targeted regions were
amplified by Hot-Start PCR and the PCR products were
cleaned up using Shrimp Alkaline Phosphatase/Exonu-
clease I mix. Each PCR amplicon was sequenced from
both forward and reverse directions, using the Big Dye
Terminator chemistry and the ABI 3730xl platform.
Sequence trimming
Phred, a base call program obtained from Dr. Brent
Ewing at The University of Washington http://www.
phrap.org/phredphrapconsed.html, was used to obtain
the DNA base sequences and the associated quality
scores from each sequence trace. Then, lucy, a sequence
cleaning program obtained from the J. Craig Venter
Institute http://www.jcvi.org/cms/research/software/,
was used to trim off low quality bases from each end of
the sequences.
Mutation detection
Both forward and reverse sequences of each amplicon
were used to assemble the final sequence for each exon.
The assembled sequences from the tumor/normal paired
samples were aligned using the multiple sequence align-
ment program CLUSTALW, and each alignment was
manually inspected to ensure its correctness. Sequence
changes (e.g. indels, base substitutions) were identified by
finding base changes between each tumor and its match-
ing normal sequences. A cut off phred quality score of 20
was used to reduce false positives due to sequencing
errors, ensuring that only high quality bases with an
error rate of ≤ 1% were eligible for mutation findings.
qRT-PCR with mouse genes
Primer design
The primers were designed with Primer3 (frodo.wi.mit.
edu/primer3/), with the criteria of 20 ± 1 mer primers,
Tm of 60 ± 1°C, < 2 G or C residues in the final 5 bases,
an amplicon size of 65-75bp, and unique sequences when
compared to the RefSeq-RNA database from GenBank
and the genomic sequences of the species involved. The
primers were “TCTCTCCAAGCAGCGAGAAT” and
“ACTTGGACGCAGCTGATTCT” for APC; “AGAAGA-
TAGACCGCCTGCAA” and “GCTGAGCTCTGACC-
GAAGTT” for MCC; “GATCGGTGGCTCCATCCTGG”
and “GCCGGACTCATCGTACTCCTG” for b-actin; and
“AGCGAGCGACCAAAGGAACC” and “GCATGTC-
TAAGTACGCACGGC” for 18 S Ribosomal subunit.
The primer sequences are all indicated in the 5′-t o
3′-direction.
RNA extraction
The total RNA was extracted using the STAT-60
reagent from Tel-Test (Texas), following the manufac-
ture’s instruction. Then, the amount of RNA was deter-
mined spectrophotometrically, and only samples with a
260/280 ratio of ~1.8 were subjected to further analyses
described below.
cDNA synthesis
For each sample, 6 μg RNA was treated with DNase to
degrade any residual genomic DNA in the RNA samples
using the TURBO DNA-free™ k i tf r o mA m b i o n( T e x a s ) .
Then, 1 μg RNA was used for cDNA synthesis with the
RETROscript kit from Ambion, following the manufac-
ture’s instructions.
qRT-PCR reactions
qRT-PCR reactions were performed in triplicates with
each well containing 10 μli Q ™ SYBER Green Supermix
Ji et al. BMC Cancer 2010, 10:426
http://www.biomedcentral.com/1471-2407/10/426
Page 3 of 13from Bio-Rad, 500 nM primers each, and 0.25 μlc D N A
synthesized above in a total reaction volume of 20 μl,
with an iCycler iQ Real-Time PCR machine. The ampli-
fication condition was: 95°C for 10 seconds, 65°C for
45 seconds, and 78°C for 20 seconds for a total of
40 cycles.
qPCR with mouse genes
The same protocol described for qRT-PCR above was
followed except that 10 ng genomic DNA was used in
each well instead of cDNA. The primers flanking
SMAD4e x o n8( C D S 7 )w e r e“tttcttcttagGGCCAGTT-
CAC” and “tacCAGGATGATTGGAAATGG"; and for
exon 4 were “CCCACTGAAGGACATTCGAT” and
“CTGTACGTCTCCGTTGATGC”.T h ep r i m e r so f
reference controls were “TCCAGGTAGCAATGAC-
GAGA” and “GCGCAGAGCTTGTGTGTAAA” for
MBD2 exon5; “AGAACTGGTCAGTGCCTTGG”,a n d
“TCT GCTGACTGCTGGTGTCT” for MCC exon 16;
“AGCAGGATTGCGTCCATATC” and “CAGTTG-
GAGTTGTCGAGCAG” for MBD1 exon 10; and
“GATGTGCCTATGGTCCTGGT” and “CCTGAGC
CTGTTTCGTGTCT” for KRAS exon 4.
Mouse tumor aCGH analysis
The oligo arrays were performed using the 385 K oligo-
nucleotide arrays from Roche NimbeGen, with each
chip containing 385,000 oligo probes of ~50 bp unique
sequences selected across the mouse genome, providing
a resolution of 1 probe every 5 kb on average. Amplifi-
cations and deletions were identified by our newly
developed software tool SEG (manuscript submitted).
Results
Human 5q22.2 and 18q21.1-q21.2 are evolutionarily
unstable
Through comparison of the genomic sequences of the
human and other species (i.e., chimp, orangutan, rhesus
macaque, marmoset, mouse, rat, guinea pig, dog, cow,
opossum, platypus, chicken, lizard, xenopus, fly, worm,
mosquito, honey bee, yeast, zebrafish, puffer fish, tetrao-
don, and ciona), we found that regions 5q22.2 and
18q21.1-q21.2 are both evolutionarily unstable (com-
pared with an average human genomic site). Genomic
rearrangements were identified in many nonhuman spe-
cies (i.e., 10 out of 14 species shown in Figure 2 and all
other species except xenopus listed above but not
shown in Figure 2), within these sites and/or nearby
regions. Hence, while genes of each region are clustered
in the human genome, they are scattered on two or
more distinct loci in the genome of many other species.
With several evolutionary rearrangement breakpoints
identified, the human 5q22.2 region has been divided into
several distinct loci in the mouse genome (Figure 2A). As
a result, even though APC and MCC are less than 200 kb
apart in the human genome, they are 10 Mb apart in the
mouse genome (likely due to an inversion event occur-
ring in the mouse lineage [18]). For human 18q21.1-
q21.2 (Figure 2B), although the genes are clustered in
the mouse genome as in the human genome, break-
points were identified both upstream (4.5 Mb from
SMAD2) and downstream (2.5 Mb from MBD2)o ft h e
region [18,19].
Other inter-species rearrangement breakpoints, shown
in Figure 2, are also located at intergenic regions, and
thus have not disrupted the exon/intron structure of
any genes. Compared to the rest of the genome, nearly
every breakpoint region contains significantly more
repetitive sequences (up to 90%). For example, the one
between APC and MCC contains 61% of total repeats
and 26% of Alus. These percentages are significantly
h i g h e rt h a nt h o s eo ft h ew h o l eg e n o m e[ 2 0 - 2 2 ]a n d
these repetitive sequences could have mediated non-alle-
lic homologous recombination, facilitating inter-species
rearrangements [20].
Human 5q22.2 and 18q21.1-q21.2 regions, constantly
disrupted in human CRCs, encode CRC-driver genes as
well as an apparent CRC passenger gene and another
questionable gene
SMAD4 versus DCC in 18q21.1-q21.2
The human 18q21.1-q21.2 region, constantly disrupted
in human CRC [15,16], encodes the bona fide CRC gene
SMAD4 (Figure 1), which is an essential player of the
transforming growth factor-b (TGF-b) signaling path-
way. This pathway controls a diverse set of cellular
processes including cell proliferation, recognition, differ-
entiation, and apoptosis during embryogenesis and in
mature tissues [23,24]. SMAD4 has indeed been found
to be deleted in human CRCs [25-27], and its driver
role in tumorigenesis has been demonstrated through
mouse models by knocking out either SMAD4 alone or
both APC and SMAD4 together [28,29].
Another gene, DCC (deleted in colorectal cancer [30]),
is found to be in close proximity to SMAD4 in the
human 18q21.1-q21.2 region (Figure 2). However, unlike
SMAD4, the mouse model studies have indicated that
DCC is unlikely to be a CRC-driver. This is because in
mice, inactive DCC through targeted mutagenesis [31]
or spontaneous mutations (Mouse Genome Informatics,
http://www.informatics.jax.org) have no effect on the
intestine or on tumorigenesis within the intestine.
APC versus MCC in 5q22.2
The human 5q22.2 region encodes the best known CRC
tumor suppressor, APC (adenomatous polyposis coli).
The alteration of APC is the earliest event yet identified
in human CRCs, and it is estimated that greater than
85% of human CRCs have somatic mutations of this
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firmed by various mouse models (see Mouse Genome
Informatics at http://www.informatics.jax.org). APC
encodes a multifunctional protein whose tumor suppres-
sing function is thought to come from its ability to
destabilize b-catenin, a key effector in the Wnt-signaling
pathway [32-35]. Other roles of APC include mediation
of intercellular adhesion, stabilization of the cytoskele-
ton, and possible regulation of the cell cycle and apopto-
s i s[ 3 6 ] .I n d e e d ,l o s so fAPC activity has a dramatic
effect on the mouse intestinal epithelium. This has been
demonstrated by altered crypt/villus architecture,
Figure 2 Human 5q22.2 and 18q21.1-21.2 are evolutionarily unstable. A: Human 5q22.2 (112-113 Mb) is shown as the bar with its gene-
coding regions (APC, MCC, etc.) shaded. When compared to species above (horse, rhesus, orangutan and chimp; with the orthologous
chromosome of the human chromosome 5 represented by the number inside the bar), no rearrangements were found. However, when
compared to species below (rat, mouse, pig, dog, cow, opossum, and platypus) or nearby (chicken and lizard), rearrangements were identified
within the region. Rearrangement breakpoints are indicated by gaps between the bars, with numbers inside each bar representing the Mb
region of a chromosome (e.g., “18, 25.2-26.8” represents 25.2-26.8 Mb of chromosome 18) or a supercontig/ultra-contig/scaffold (e.g., S1,0-3.4).
“Un” stands for chromosome “Unknown” in the released genome assembly. The arrow of each bar designates the sequence direction, and a
dished arrow indicates that the homology to the human extends beyond 5q22.2 shown here. B: Human 18q21.1-q21.2 (43-50 Mb) encodes
three SMAD genes, two MBD genes, DCC, and a number of other genes (not shown). The same as above, no rearrangements were found when
compared to species shown above the human. However, when compared to the species shown below, rearrangements were found within the
region and/or nearby. In addition, many sequences are missing in the orthologous chicken and lizard sites (demonstrated by large gaps in the
alignment). The question mark “?” inside or below the cow bars indicates that the human-cow alignment at this region has not been completely
resolved.
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apoptosis, as well as altered gene expression [37].
Besides the bona fide tumor suppressor APC,5 q 2 2 . 2
also encodes the gene MCC (mutated in colorectal can-
cer [38]). However, at present no evidence indicates
whether MCC alteration contributes to human CRC
development and progression or not.
Comparative studies with human and mouse tumors
We conducted further experimental analyses focusing
on the APC/MCC gene pair in 5q22.2; however, we did
n o td os ow i t ht h eSMAD4/DCC pair in 18q21.1 for
several reasons. First, unlike DCC where the mouse
models have somewhat excluded its role in CRC [31]
(see the previous section), there have been no further
studies on MCC that directly or indirectly suggest or
dispute its role in cancer since its alteration in human
CRC was first reported [38]. More importantly, we were
conducting comparative studies between human color-
ectal tumors and tumors from B6 Apc
Min/+ mice. As
shown in Figure 2, unlike SMAD4 and DCC that are
physically close in both genomes, APC and MCC are
adjacent (< 200 kb) in the human genome but distant
(> 10 Mb) in the mouse genome. Thus, the APC/MCC
pair provided an excellent example to showcase our
cross-species comparison strategy, utilizing the differ-
ence in the genomic location of orthologous genes in
different species to distinguish between cancer driver
and passenger alterations.
Apc
Min/+ is a well-characterized mouse model of
human CRC [10,11,39-42]. The Min (multiple intestinal
neoplasias) allele of APC was induced by ethylnitro-
sourea (ENU), and carries a point mutation that gener-
ates a premature stop codon (see the following section
for more details) [10,11]. Studies [41,42] indicated that
the remaining wild type copy of APC is lost through
somatic recombination during intestinal tumorigenesis
in B6 Apc
Min/+ mice. Thus, tumors from this model
most closely resemble the majority of human sporadic
CRCs where the APC activity is lost.
Bidirectional exon-resequencing
To detect sequence mutations (e.g., indels, base substi-
tutions, and small inversions), we performed bidirec-
tional exon-resequencing analyses on the APC and
MCC genes. Along with other genes in 18q21.1-q21.2
(see the later sections), we were able to design primers
for 78 out of 79 total exons. With these primers we per-
formed PCR amplification using five pairs of colonic
tumor (4-5 mm in size) and matching-normal tissue
samples from two B6 Apc
Min/+ mice. We then
sequenced each PCR product from both directions. Out
of 3,264 total sequencing attempts (large exons required
sequencing several overlapping PCR products), 3,076
successful sequences were achieved. Each successful
sequence had at least 100 bp high quality bases (having
ap h r e dq u a l i t ys c o r eo f≥ 20 and a base call error rate
of ≤ 1%) after trimming off low quality bases. For com-
parison purposes, we also performed the same sequen-
cing process on 22 pairs of human Dukes B sporadic
colorectal tumors and their matching-normal tissue
samples, and obtained 8,342 successful sequences from
9,360 total sequencing attempts. Thus, we achieved a
sequencing success rate of 94% for the mouse samples
and 89% for the human samples.
Sequence mutation identification
Following sequencing, we assembled the sequences for
each exon using its forward and reverse sequences,
based on the reference exon sequence from the pub-
lished human and mouse genomes. With the assembled
sequences, we performed multiple sequence alignments
for the tumor/normal pairs using the CLUSTALW pro-
gram. We then manually examined each alignment to
ensure that the sequences were, indeed, correctly aligned
(see Additional file 1 for the sequence alignments).
We identified regions in the alignment that displayed
different base(s) between the paired tumor and normal
sequences. To reduce false positives due to sequencing
errors, we ignored bases that have a quality score of
below 20. Importantly, considering that missense muta-
tions do not necessarily change protein function as
severely as nonsense or frameshift mutations, we pri-
marily focused on base changes resulting in premature
stop codons and indels within coding exons. Thus, we
largely ignored base changes inside noncoding exons as
well as missense mutations within coding exons.
APC was disrupted in both human and mouse tumors,
whereas MCC was disrupted in human tumors but intact
in mouse tumors
APC was disrupted in both human and mouse tumors
As described previously [10,11], the Min allele of
Apc
Min/+ was created by an ENU-induced T®Ap o i n t
mutation at base 2,549 of the APC gene. This changes
codon 850 from leucine-coding “UUG” to stop codon
“UAG” (mouse APC has a total of 2,843 codons with
8,529 bases total). In our study, the base in position
2,549 was independently sequenced three times for
e a c hs a m p l ea n df o u n dt ob ee i t h e r“T” or “A” in the
resulting sequences (Figure 3). This indicated that,
within the same sample, some DNA molecules had “A”
whereas others had “T” at this position. However, the
wild type base “T” was more dominant in normal sam-
ples whereas the mutant base “A” was more dominant
in tumor samples (based on the phred quality scores
or the base call accuracy shown in Figure 3). These
findings were consistent with the heterozygous nature
of the APC locus, having both wild type and Min
alleles in Apc
Min/+ m i c e ,a sw e l la sw i t hp r e v i o u ss t u -
dies indicating that the wild type copy of APC was lost
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two tumors (8762-1T and 8762-2T, from the same
mouse) where the wild type base “T” was slightly more
dominant, we identified a “GG” insertion at base 6,448,
also known as codon 218 (Figure 3). This causes a fra-
meshift for the rest of the protein, indicating that
these two tumors did not retain their wild type APC
allele either. Thus, besides somatic recombination, B6
Apc
Min/+ mice could lose their wild type APC copy by
acquiring additional sequence mutations.
Except for these two abnormalities, we did not find
any other stop codon or indel mutations for the mouse
APC (see Additional file 1). For the human APC,h o w -
ever, we identified significantly more mutations. Stop
codons and indels were found within coding exons
2-4, 6, 8, 9, 11 and/or 15 in the 22 human tumors ana-
lyzed (see Additional file 1). This is consistent with lit-
erature reports that APC is altered in a vast majority
of the human sporadic CRCs [13], and reveals the het-
erogeneity of sporadic human cancers. The APC gene
results described above demonstrated the effectiveness
of our re-sequencing protocol and data-analyzing
pipeline.
MCC was disrupted in human tumors but intact in mouse
tumors
We sequenced each of the 17 coding exons of the
mouse MCC gene with a total of 2,333 bases, and found
no mutations in the mouse tumors (see Additional
file 1) (our qPCR analysis with several of its exons did
not reveal large copy number changes either). However,
stop-codons were identified in several MCC exons in
many of the human tumors studied (see Additional
f i l e1 ) .T h i si sc o n s i s t e n tw i t hp r e v i o u ss t u d i e st h a t
reported MCC being disrupted in human CRC [38].
T h u s ,u n l i k eb o n af i d eC R Cg e n eAPC, MCC is dis-
rupted in human tumors but intact in mouse tumors in
terms of its exon sequences.
Confirmation of MCC integrity in mouse tumors by qRT-PCR
To confirm that MCC is intact in mouse tumors, we
performed qRT-PCR analyses to examine its expression.
In order to select proper normalization controls, we
tested 4 genes (b-actin, glyceraldehyde 3-phosphate
dehydrogenase or GAPDH, 18 s ribosomal subunit,a n d
b-2-microglobulin), chosen based on a literature search.
Through examination of the variation of expression in
ten pairs of mouse tumor samples and matching-normal
Figure 3 Sequence mutations of APC in the tumors from B6 Apc
Min/+ mice. Top: the bases and their quality score in parenthesis, e.g. T(46),
are the outputs from the base-call program phred for the base 2549 of the mouse APC gene. The three bases next to each sample (e.g., 8762-
1N), ordered by their quality score or base-call accuracy (the base call error rate equals to 10
-quality score; thus a higher score means a more
accurate base call), are from three separate sequences generated for the sample. Tumors 1-4 and their matching normal tissue samples were
from mouse ID 8762, whereas tumor 5 and its matching normal sample were from mouse ID 8791 (thus, 8762-1N and 8762-1T are paired
normal/tumor samples, and so on). Middle and bottom: The first sequence alignment is for bases 2493-2552 of mouse APC. Using the most
accurate base (i.e., having the highest quality score) for base 2549 as indicated above, tumors 3-5 have a T- > A mutation (in red/green color)
creating a premature stop codon. The remaining two tumors (8762-1T and 8762-2T) have a “GG” insertion at base 6448 of APC, as shown in the
second sequence alignment which is for bases 6393-6450 of mouse APC. “Consensus” stands for the corresponding sequence obtained from the
published mouse genome.
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subunit as the normalization control genes, because no
significant changes were found across the samples. We
also included the APC gene in the study.
A total of ten pairs of adenoma and matching-normal
tissue samples from several B6 Apc
Min/+ mice were ana-
lyzed. A t-test was performed to examine the differences
in the normalized Ct values between paired adenoma
and normal samples (Ct is the threshold cycles: the
number of cycles at which the earliest measurable fluor-
escence signal can be detected in a qPCR assay; a higher
Ct value means fewer templates). Significant statistical
changes were observed for APC (t = 1.96 and p = 0.08),
however, not for MCC (t = 0.71 and p = 0.5). This indi-
cates that APC was altered whereas MCC was intact in
the adenomas at the expression level, and is consistent
with the resequencing results described above.
SMAD4 was disrupted in both human and mouse tumors
We investigated the SMAD4 gene in both human and
mouse tumors via sequencing and other methods for a
number of reasons. First, SMAD4 alteration contributes
to human colorectal tumorigenesis at a relatively early
stage, late adenoma formation (Figure 1). Because the
mouse tumors are adenomas, we would like to know if
SMAD4 is altered or intact in these tumors. This infor-
mation would provide one critical piece of evidence sup-
porting whether or not tumorigenesis of Apc
Min/+ in
mice follows similar pathways as in humans (Figure 1).
Similar pathways of tumorgenesis in both species are a
prerequisite for our cross-species strategy for distin-
guishing between cancer drivers and passengers.
Besides SMAD4, we also sequenced a few other genes
in 18q21.1-q21.2 (Figure 2B), including methyl-CpG
binding proteins MBD1 and MBD2, as controls. While
we did not find stop codon or indel mutations in coding
exons of the two genes in the mouse tumors, we did
identify such mutations in exons 5, 6, 8, 13 of MBD1
(but not in any MBD2 exons) in the human tumors (see
Additional file 1). These findings are consistent with the
5q22.2 sequencing analysis described above, which
revealed an overall higher sequence mutation rate in the
human tumors than in the mouse tumors, supporting
that our sequencing analysis was run properly as well
with the 18q21.1-q21.2 genes.
SMAD4 was disrupted in mouse tumors
To determine whether SMAD4 was disrupted or intact
in the mouse tumors, we first sequenced its exons. For
coding exon 7 of mouse SMAD4,w ef o u n dt h a t ,w h i l e
60% of the matching-normal samples were sequenced
successfully, all tumors failed the sequencing procedure.
However, the remaining 10 coding exons (mouse
SMAD4 has 11 coding exons with a total of 1,656 bases)
were sequenced successfully with all tumor and normal
samples (see Additional file 1). To determine whether
the sequencing failure of coding exon 7 in the tumors
was due to large sequence deletions or technical pro-
blems in our sequencing procedure, we performed
further analyses as described below.
Confirmation by qPCR
Because qPCR is an effective strategy for detecting large
deletions, we performed this analysis on a total of 10
adenomas along with their matching normal samples
from several B6 Apc
Min/+ mice. We examined exon 7
(with which sequencing succeeded on most normal sam-
ples but failed on the tumors) and exon 4 (with which
sequencing succeeded on all tumor/normal samples and
no mutation was found) of SMAD4. We examined these
along with four reference controls including exon 16 of
MCC,e x o n5o fMBD2,e x o n1 0o fMBD1,a n de x o n4
of KRAS. These reference exons were chosen because
they are all from single-copy genes in the genome and,
more importantly, no large copy number changes were
observed between tumor and normal samples. Our
sequencing (and expression in the case of MCC)a n a -
lyses revealed no alterations in MCC, MBD2 and MBD1
exons in mouse tumors (see above). For KRAS,w ed i d
not find any studies that reported copy number changes;
most alterations identified were point mutations which
would interfere less severely with the qPCR analyses,
compared with large amplifications/deletions.
We noted that 8 of the 10 total tumors had a higher
Ct value than their matching normal samples for exon
7o fSMAD4. This, however, was not observed for
exon 4 of SMAD4 and the four reference control
exons described above. To conclude these observations
more quantitatively, we performed t-test analyses to
examine the Ct differences between the tumors and
their matching normal samples. We found that the dif-
ferences were significant for SMAD4 e x o n7( t=2a n d
p is between 0.05-0.025) but insignificant for the other
e x o n se x a m i n e d( t< 0 . 5a n dp>0 . 2 5 ) .T h e s er e s u l t s
were consistent with the sequencing analyses, and indi-
cated that SMAD4 exon 7 was likely deleted in the
mouse tumors.
Because heterogeneity is expected for somatic muta-
tions, we were puzzled by the apparent homogeneity
observed for SMAD4 alteration in the mouse tumors
(i.e., only exon 7 found to be disrupted). SMAD4 exon 7
is 51bp in size and is separated from the previous exon
by an intron of 1.3 kb and from the following exon by
another intron of 7.3 kb. Thus, the genomic regions sur-
rounding SMAD4,e x o n7 ,a m o u n tt o8 . 6k b .T h e s e
regions were found to harbor more L1 s and simple
repeats with a low (< 10%) sequence divergence among
the copies (i.e., younger repeats) and to be less con-
served in other species (e.g., a gap of 5.8 kb for mouse
and 4 kb for humans were found when aligning the
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the rest of the gene (see Additional file 1). We hypothe-
size that deletions of exon 7 could have occurred via
homologous recombination between the two highly
identical AT-rich repeats inside its two flanking introns
(see Additional file 1). Hence, the apparent homogeneity
could have arisen from the fact that sequences around
exon 7 are intrinsically more unstable, compared with
those of other parts of the gene. A somewhat similar
situation has been reported for the BRCA1 gene locus,
of which the structural instability revealed by evolution-
ary analyses may mostly originate from Alu-mediated
rearrangement [43].
Our hypothesis was partially supported by the obser-
vation of “subtle” chromosome instability (CIN) in the
mouse tumor genomes. By analyzing several mouse
tumors with Roche NimbleGen’s 384 K oligonucleotide
comparative genomic hybridization (CGH) arrays, we
found that ~4% of the genomic sequences of the
tumors were amplified/deleted, compared to 1% when
hybridizing a normal sample against another normal
sample. This is consistent with a recent study that
observed misoriented spindles and misaligned chromo-
somes associated with tetraploid genotypes in dividing
crypt cells within the small intestines of APC
Min/+
mice [44]. However, we must emphasize the word
“subtle” for the observed mouse CIN because, for the
human tumors displaying CIN, the amplified/deleted
sequences amount to >10% of the genome. This, per-
haps, explains why other studies did not find CIN in
Apc
Min/+ tumors [45]. The reason that “subtle” CIN
was detected here is, most likely, due to the high reso-
lution of the oligo arrays being used (one probe every
5-6 kb across the genome), and, as far as we know, we
are the only group that has used such high density
arrays on these mouse tumors.
With the Ct difference between the tumors and their
matching normal samples ranging from -0.1 to 2, the 10
tumors used in qPCR analyses showed more heteroge-
neity than the 5 tumors used in the sequencing analysis
for SMAD4 exon7 (all tumors failed the sequencing pro-
cess). One likely reason is that these 5 tumors were con-
siderably larger than those used in qPCR analyses (4-5
mm versus 1-2 mm in size). Therefore, they were at
later tumor progression stages, where more extensive
genomic instability develops and more genomic
abnormalities accumulate.
SMAD4 in human tumors
A high sequencing failure rate was also found in the
human homologue of the mouse SMAD4 coding exon 7.
There were also disruptions in a number of other cod-
ing exons (see Additional file 1), indicating that SMAD4
was also altered in the human tumors, consistent with
previous studies [25-27].
P53 also altered in mouse tumors
Besides genes of 5q22.2 and 18q21.1-q21.2 described
above, we also investigated genes with high mutation
prevalence (i.e., P53, KRAS,a n dPIK3CA), as well as
those with intermediate-low mutation prevalence (i.e.,
SMAD2 and SMAD3) in human CRC [46]. This would
provide more evidence to evaluate the molecular simila-
rities of tumorigenesis between human CRC and the
Apc
Min/+ model.
We conducted qRT-PCR analysis on these genes along
with two reference genes b-actin and GAPDH,w i t h1 2
matched colon adenomas and normal tissue samples
from several Apc
Min/+ mice. After normalization with b-
actin, we performed t-tests to determine if the Ct differ-
ence between the tumors and normal samples is signifi-
cant for each gene. We found that P53 was significantly
altered in these tumors (t = -4.8; p < 0.0001). However,
we did not detect significant changes for the other
genes (KRAS, PIK3CA, SMAD2,a n dSMAD3), although
their t-values are >10 times larger than that of GAPDH
(see Table s1 in Additional file 1). Hence, this analysis
indicates that P53 was also altered in the mouse tumors,
adding another piece of evidence supporting the mole-
cular similarities between human CRC and the mouse
model. For the other genes, further analysis (e.g.,
sequencing) are clearly needed to determine if they are
intact or disrupted in the mouse tumors.
Discussion
The ability to distinguish between cancer driver and
passenger alterations has been a central aim of cancer
research. To achieve this, we are developing a cross-
species comparison strategy by taking advantage of the
difference in the genomic location of orthologous genes
between the human and other mammals. To showcase
this strategy, we conducted a pilot study focusing on
genes APC and MCC, which are adjacent in 5q22.2 of
the human genome but distant in the mouse genome
(Figure 2). We found that, consistent with literature
reports, both genes were disrupted in human colorectal
tumors. However, in the mouse tumors, only bona fide
CRC gene APC was disrupted whereas MCC appeared
to be intact. This indicates that MCC alteration may not
be a driver (but rather a passenger) of colorectal tumori-
genesis, and we hypothesize that its disruption in human
CRCs could merely be a result of its close proximity to
APC in the human genome (Figures 2 &4), as rationa-
l i z e da sf o l l o w s .W h e nm u t a g e n sa c to nt h eAPC locus
causing APC mutations, the neighboring MCC gene is
accidently exposed to the mutagens (consistent with
this, we also found a significant amount of nonsense
mutations and indels in another neighboring gene DP1
or d e l e t e di np o l y p o s i s1 ; see Additional file 1). Because
MCC is 10 Mb away from APC in the mouse genome
Ji et al. BMC Cancer 2010, 10:426
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tially have no effect on MCC. Hence, MCC could simply
be like other background genes with no causative roles
(Figure 4), and thus no enrichment of MCC alteration
was observed in the mouse tumors. Perhaps a more
familiar analogous example of this situation would be: a
passenger was injured in a car accident that was caused
by the driver of the car (MCC vs. APC in the human
tumors); however, if the passenger had been sitting in a
different car, he/she would, most likely, have been
injury-free (MCC vs. APC in the mouse tumors).
This pilot study demonstrates the promise of using
this cross-species comparative strategy to identify cancer
driver alterations. Nearly 10,000 loci have been found to
be disrupted in human colonic polyps [47]; clearly, it
would be useful to know which disruptions are colorec-
tal tumorigenesis-drivers and which ones are not. Sev-
eral groups, including us, have built a high resolution
synteny/rearrangement map between the human and
mouse genomes [8,9,18], and identified ~400 inter-
species rearrangements. Thus, there are many places
like the APC/MCC l o c u si nt h eh u m a ng e n o m e .P r o -
v i d e dt h a tt h eB 6Apc
Min/+ model is clearly demon-
strated to share similar cancer progression pathways as
human CRCs (discussed below), expanding this pilot
project to the entire genome would potentially identify
many targets like MCC, facilitating bona fide CRC gene
discovery.
The disruption of SMAD4 in mouse tumors raises the
possibility that B6 Apc
Min/+ mice might share a similar
genetic pathway of tumorigenesis as human CRC shown
in Figure 1 [12,13], especially considering that SMAD4
is distantly located from the ENU-induced Apc
Min/+
locus (Figure 2). This is further supported by our obser-
vation that the expression of P53 is also significantly
altered in mouse tumors. Consistent with these, several
recent studies reported that a subset of the genes, with
expression altered in Apc
Min/+ adenomas, were con-
firmed to be changed in human CRCs as well [40,48]. In
addition, our high density aCGH array analysis found
subtle CIN in the genome of the mouse adenomas,
which is consistent with the human colorectal tumori-
genesis model where CIN is an early event (Figure 1).
Of course, a significant amount of work is needed to
conclude that APC
Min/+ tumorigenesis indeed share the
similar pathway as human CRC as shown in Figure 1,
such as investigating other contributors such as KRAS
gene alteration.
Besides conducting further studies with B6 Apc
Min/+,
other mouse models should also be explored. This is
especially needed when comparing more genetically
homogeneous gene-knockout mouse models to more
genetically heterogeneous sporadic human CRCs. The
APC
Min/+ model may only represent a subset of sporadic
human CRCs. This could be improved by studying other
mouse models, such as SMAD4-knockout mouse models
[28,29] and those described in a recent publication
(azoxymethane or AOM, Smad3
-/-,a n dTgfb1
-/- Rag2
-/-)
[48]. Importantly, tumors from APC
Min/+ are mostly
adenomas, and obviously APC
Min/+cannot represent late
stage human CRCs. Other models, such as the one
described by Hinoi et al. [49] that aims to model transi-
tion from adenoma to adenocarinoma, should be inves-
tigated. Of course, sporadic cancers from animal models
Figure 4 Our study indicates that MCC alteration is unlikely to be a driver of colorectal tumorigenesis at early stages (top). The bottom
illustrates our hypothesis that alteration of MCC in human CRCs occurs as a result of its proximity to APC in the human genome (~200 kb apart).
However, because MCC is distant from APC (~10 Mb apart) in the mouse genome, agents that caused APC alternations have no effect on MCC;
thus, like other genes without causative roles in tumorigenesis, MCC remains intact in the mouse tumors.
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cancers [50], but sporadic cancers are rare in mice and
difficult to obtain in other species. However, essentially
an unlimited amount of tumors could be accessed with
the genetically modified mouse models, which greatly
facilitates the studies.
Unlike strategies such as gene knockout mouse mod-
els, our approach does not provide direct evidence to
determine whether a gene alteration is a cancer driver
or passenger. However, this approach is much more
cost- and time-effective, as performing large scale ana-
lyses, such as microarray or sequencing studies, could
allow all the genes and the entire genome of an organ-
i s mt ob ee x a m i n e di nas i n g l ee x p e r i m e n t .O u r
approach could quickly narrow down the list of cancer-
driver gene alteration candidates, which then can be ver-
ified by direct approaches, such as gene knockout mouse
models.
Conclusions
We conducted a pilot study to demonstrate the effec-
tiveness of a cross-species comparison strategy to distin-
guish between cancer driver and passenger alteration
candidates, by utilizing the difference in the genomic
location of orthologous genes and genomic loci between
the human and other mammals. This pilot study
focused on the human 5q22.2 and 18q21.1-q21.2
regions, which are frequently disrupted in human CRCs.
They also encode bona fide cancer genes (e.g., APC,
SMAD4), an apparent passenger gene, DCC, and genes
that are disrupted in human CRCs but whose roles in
cancer remain unclear (e.g., MCC). Both regions are
evolutionarily unstable. As a result, APC and MCC are
adjacent in the human genome but are distant in the
mouse genome. By studying the same orthologous genes
in colon tumors from humans and the CRC mouse
model B6 Apc
Min/+, we found that bona fide cancer
genes APC and SMAD4 were disrupted in both species.
However, the questionable cancer gene MCC appeared
to be intact in the mouse tumors, unlike in the human
tumors. This indicates that MCC may not be a driver of
colorectal tumorigenesis, and that its alteration in
human CRCs could be due to its close proximity to
APC in the human genome (Figures 2 &4). This pilot
study demonstrates the promise of using this cross-
species comparative genomics and oncology strategy to
identify cancer-causative alterations. Once the B6
Apc
Min/+ model is clearly demonstrated to share similar
tumorigenesis pathways as in humans CRCs (Figure 1),
expanding this pilot project to the entire genome would
potentially identify many targets like MCC, facilitating
cancer driver gene alteration discovery.
Additional material
Additional file 1: Supporting Material. This file provides additional
analyses and information to support the conclusions described in the
main text.
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